Effectiveness and safety of drugs for obesity

BMJ, Год журнала: 2024, Номер unknown, С. e072686 - e072686

Опубликована: Март 25, 2024

Abstract Recent publicity around the use of new antiobesity medications (AOMs) has focused attention patients and healthcare providers on role pharmacotherapy in treatment obesity. Newer drug treatments have shown greater efficacy safety compared with older treatments, yet access to these is limited by providers’ discomfort prescribing, bias, stigma obesity, as well lack insurance coverage. Now more than ever, must be able discuss risks benefits full range available patients, incorporate both guideline based advice emerging real world clinical evidence into daily practice. The tremendous variability response means that clinicians need a flexible approach takes advantage specific features medication selected provide best option for individual patients. Future research needed how practice settings, potential combination therapies, cost effectiveness medications. Several are being evaluated ongoing trials, suggesting future obesity bright.

Язык: Английский

---

Therapeutic advances in obesity management: an overview of the therapeutic interventions

Frontiers in Endocrinology, Год журнала: 2024, Номер 15

Опубликована: Апрель 23, 2024

Obesity has become a global epidemic in the modern world, significantly impacting healthcare economy. Lifestyle interventions remain primary approach to managing obesity, with medical therapy considered secondary option, often used conjunction lifestyle modifications. In recent years, there been proliferation of newer therapeutic agents, revolutionizing treatment landscape for obesity. Notably, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, liraglutide, and recently approved dual GLP-1/GIP RAs agonist tirzepatide, have emerged effective medications resulting significant weight loss. These agents not only promote reduction but also improve metabolic parameters, including lipid profiles, glucose levels, central adiposity. On other hand, bariatric surgery demonstrated superior efficacy achieving addressing overall imbalances. However, ongoing technological advancements, is an debate regarding whether personalized medicine, targeting specific components, will shape future developing novel obesity management.

Язык: Английский

---

Current and future pharmacotherapies for obesity in children and adolescents

Nature Reviews Endocrinology, Год журнала: 2023, Номер 19(9), С. 534 - 541

Опубликована: Июнь 19, 2023

Язык: Английский

---

Epigenetics in obesity: Mechanisms and advances in therapies based on natural products

Pharmacology Research & Perspectives, Год журнала: 2024, Номер 12(1)

Опубликована: Янв. 31, 2024

Obesity is a major risk factor for morbidity and mortality because it has close relationship to metabolic illnesses, such as diabetes, cardiovascular diseases, some types of cancer. With no drugs available, the mainstay obesity management remains lifestyle changes with exercise dietary modifications. In light tremendous disease burden unmet therapeutics, fresh perspectives on pathophysiology drug discovery are needed. The development epigenetics provides compelling justification how environmental, lifestyle, other factors contribute pathogenesis obesity. Furthermore, epigenetic dysregulations can be restored, been reported that certain natural products obtained from plants, tea polyphenols, ellagic acid, urolithins, curcumin, genistein, isothiocyanates, citrus isoflavonoids, were shown inhibit weight gain. These substances have great antioxidant potential interest they also modify mechanisms. Therefore, understanding modifications target primary cause mechanisms anti-obesity effects phytochemicals prove rational strategies prevent develop novel therapeutic interventions. Thus, current review aimed summarize advances in therapies based provide evidence several targets.

Язык: Английский

---

Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy

Obstetrics and Gynecology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 23, 2025

Obesity is a chronic condition that causes significant morbidity and mortality in people the United States around world. Traditional means of weight loss include diet, exercise, behavioral modifications, surgery. New medications, glucagon-like peptide-1 receptor agonists, are revolutionizing management but have implications for fertility pregnancy. associated with infertility may affect response to ovulation induction medications. In pregnancy, obesity increases risks spontaneous abortion, birth defects, gestational diabetes, hypertensive disorders cesarean delivery, stillbirth. Lifestyle changes alone not improved outcomes. Glucagon-like agonists new medications targeting gut hormones can help achieve their goals contraindicated Obstetrician-gynecologists should work patients manage these before they become pregnant, between pregnancies, after delivery.

Язык: Английский

---

Aberrant expression of agouti signaling protein (ASIP) as a cause of monogenic severe childhood obesity

Nature Metabolism, Год журнала: 2022, Номер 4(12), С. 1697 - 1712

Опубликована: Дек. 19, 2022

Here we report a heterozygous tandem duplication at the ASIP (agouti signaling protein) gene locus causing ubiquitous, ectopic expression in female patient with extreme childhood obesity. The mutation places under control of ubiquitously active itchy E3 ubiquitin protein ligase promoter, driving generation patient-derived native and induced pluripotent stem cells for all germ layers hypothalamic-like neurons. patient's phenotype early-onset obesity, overgrowth, red hair hyperinsulinemia is concordant that mutant mice expressing homolog nonagouti. represses melanocyte-stimulating hormone-mediated activation as melanocortin receptor antagonist, which might affect eating behavior, energy expenditure, adipocyte differentiation pigmentation, observed index patient. As type escapes standard genetic screening algorithms, rescreened Leipzig Childhood Obesity cohort 1,745 patients identified four additional identical mutation, similar phenotype. Taken together, our data indicate ubiquitous likely monogenic cause human

Язык: Английский

---

Lifestyle mediators of associations among siestas, obesity, and metabolic health

Obesity, Год журнала: 2023, Номер 31(5), С. 1227 - 1239

Опубликована: Апрель 26, 2023

Abstract Objective The aim of this study was to determine the association between siestas/no siestas and obesity, considering siesta duration (long: >30 minutes, short: ≤30 minutes), test whether traits and/or lifestyle factors mediate with obesity metabolic syndrome (MetS). Methods This a cross‐sectional 3275 adults from Mediterranean population (the Obesity, Nutrigenetics, TIming, MEditerranean [ONTIME] study) who had opportunity taking because it is culturally embedded. Results Thirty‐five percent participants usually took (16% long siestas). Compared no‐siesta group, were associated higher values BMI, waist circumference, fasting glucose, systolic blood pressure, diastolic as well prevalence MetS (41%; p = 0.015). In contrast, probability having elevated SBP lower in short‐siesta group (21%; 0.044) than group. Smoking number cigarettes per day mediated BMI (by 12%, percentage by smoking; < 0.05). Similarly, delays nighttime sleep eating schedules energy intake at lunch meal preceding siestas) 8%, 4%, 5% (all Napping bed (vs. sofa/armchair) showed trend 6%; 0.055). Conclusions Siesta relevant obesity/MetS. Timing eating, lunch, cigarette smoking, location association.

Язык: Английский

---

Precision medicine of obesity as an integral part of type 2 diabetes management – past, present, and future

The Lancet Diabetes & Endocrinology, Год журнала: 2023, Номер 11(11), С. 861 - 878

Опубликована: Окт. 4, 2023

Язык: Английский

---

The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity

Biomedicines, Год журнала: 2024, Номер 12(1), С. 159 - 159

Опубликована: Янв. 11, 2024

Metabolic illnesses, including obesity and type 2 diabetes, have become worldwide epidemics that an effect on public health. Clinical investigations further exploration of these mechanisms could lead to innovative, effective, personalized treatment strategies for individuals. It is important screen biomarkers in previous studies discover what missing. Glucagon-like peptide-1's role insulin secretion glucose control highlights its diagnostic therapeutic potential. Glucose-dependent insulinotropic peptide's influence postprandial satiety weight management signifies importance understanding metabolic processes. Monocyte chemoattractant protein-1's involvement inflammation resistance underlines value as a marker. Insulin-like growth factor-binding protein-7's association with sensitivity kidney function presents it potential target diseases' management. In validating biomarkers, will be easier reflect pathophysiological processes, clinicians able better assess disease severity, monitor progression, tailor strategies. The purpose the study was elucidate significance identifying novel diabetes mellitus obesity, which can revolutionize early detection, risk assessment, Standard literature searches PubMed (MEDLINE), EMBASE, Cochrane Library were conducted year 2023 identify both original RCTs recent systematic reviews explored T2D obesity. This search produced 1964 results, then reduced randomized controlled trial reviews, producing 145 results 44 respectively. Researchers discovered associations between glucagon-like peptide-1, glucose-dependent peptide, monocyte protein-1, insulin-like protein-7. Understanding those pathogenesis offers hope improving diagnostics, treatment, prevention

Язык: Английский

---

Obesity and Nutrigenetics Testing: New Insights

Nutrients, Год журнала: 2024, Номер 16(5), С. 607 - 607

Опубликована: Фев. 23, 2024

Background: Obesity results from interactions between environmental factors, lifestyle, and genetics. In this scenario, nutritional genomics nutrigenetic tests stand out, with the promise of helping patients avoid or treat obesity. This narrative review investigates whether may help to prevent Scientific studies in PubMed Science Direct were reviewed, focusing on using The work showed that few address use tools However, most listed reported their beneficial effects weight loss. Ethical conflicts also discussed, as countries, there are no regulations standardize these tools, needs be more scientific knowledge for health professionals who interpret them. International Societies, such Academy Nutrition Dietetics Brazilian Association Study Metabolic Syndrome, do not recommend obesity, especially isolation. Advancing nutrigenetics depends strengthening three pillars: regulation evidence clinical validity, professional training.

Язык: Английский

---